Understanding 503A vs 503B Compounding Pharmacies: Key Differences for GLP-1 Access

Compounded GLP-1 medications like tirzepatide and semaglutide play a key role in weight management when branded options face shortages or when patient-specific customization is needed. But for medical practices navigating the compounding landscape, one of the most important distinctions to understand is the difference between 503A and 503B facilities.

Getting this right matters — not just for compliance, but for product quality, supply reliability, and the long-term defensibility of your prescribing program.

503A refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies. These pharmacies:

• Compound medications based on individual patient-specific prescriptions
• Operate primarily under state pharmacy board oversight
• Follow USP compounding standards (USP <795> for non-sterile, USP <797> for sterile preparations)
• Are not required to register with the FDA (though they may be subject to FDA inspection)
• Are limited in the quantity they can compound — they cannot compound in anticipation of prescriptions beyond what is reasonable

Beyond-Use Dates (BUDs): 503A pharmacies assign BUDs based on USP default standards, which are generally shorter than 503B BUDs unless supported by independent stability testing.

Best for: Individualized patient care, patient-specific formulations, practices that need customized dosing or additives (B12, glycine) tailored to individual patients.

503B refers to Section 503B of the FDCA, created by the Drug Quality and Security Act (DQSA) of 2013 in response to the 2012 NECC meningitis outbreak. These facilities:

• Are FDA-registered outsourcing facilities
• Follow Current Good Manufacturing Practice (CGMP) standards — the same standard as commercial pharmaceutical manufacturers
• Can compound without patient-specific prescriptions for office use (hospitals, clinics, medical practices)
• Undergo regular FDA inspections
• Can produce larger batch sizes for clinic stock
• Assign longer BUDs supported by stability testing

Best for: High-volume clinic supply, office-use stock, practices that need reliable batch-to-batch consistency and longer shelf life.

For med spas and clinics with individualized GLP-1 programs: 503A is the natural fit. Each patient gets a prescription tailored to their specific dose, formulation, and any additives (B12, glycine) their provider determines are appropriate.

For high-volume practices needing reliable office stock: 503B provides the supply consistency, longer BUDs, and CGMP quality assurance that high-volume programs require.

The MedClinic Partners approach: We provide access to both. Our 503A portal handles patient-specific prescriptions for medical centers. Our 503B supply relationships support non-sterile pharmacies and high-volume GLP-prescribing practices. One trusted source for both tracks.

The FDA has tightened its position on compounded GLP-1s as branded supply has stabilized. Key developments:

• The FDA removed semaglutide and tirzepatide from the shortage list in 2025, triggering restrictions on 503B bulk compounding
• 503A patient-specific compounding remains viable with proper documentation of clinical need
• "Essentially a copy" determinations have become more scrutinized — adding B12 or glycine alone may not be sufficient differentiation in all cases

Staying compliant requires working with pharmacies that track these regulatory changes in real time — which is exactly what our team does.

Request portal access →

This content is for informational purposes only and does not constitute legal or regulatory advice. Compounding regulations are subject to change. Consult with qualified legal counsel regarding your specific compliance obligations.